Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase.
Saved in:
| Title: | Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase. |
|---|---|
| Authors: | O' Donovan DH; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom. Electronic address: daniel.odonovan@astrazeneca.com., Gregson C; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Packer MJ; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Greenwood R; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Pike KG; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Kawatkar S; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, United States., Bloecher A; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, United States., Robinson J; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Read J; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Code E; Discovery Sciences R&D, 35 Gatehouse Drive, Waltham, MA 02451, United States., Hsu JH; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, United States., Shen M; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, United States., Woods H; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, United States., Barton P; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Fillery S; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Williamson B; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Rawlins PB; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom., Bagal SK; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom. |
| Source: | Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2021 May 01; Vol. 39, pp. 127904. Date of Electronic Publication: 2021 Mar 06. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Science Ltd Country of Publication: England NLM ID: 9107377 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1464-3405 (Electronic) Linking ISSN: 0960894X NLM ISO Abbreviation: Bioorg Med Chem Lett Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 33684441 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22O'+Donovan+DH%22">O' Donovan DH</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom. Electronic address: daniel.odonovan@astrazeneca.com.<br /><searchLink fieldCode="AU" term="%22Gregson+C%22">Gregson C</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Packer+MJ%22">Packer MJ</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Greenwood+R%22">Greenwood R</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Pike+KG%22">Pike KG</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Kawatkar+S%22">Kawatkar S</searchLink>; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, United States.<br /><searchLink fieldCode="AU" term="%22Bloecher+A%22">Bloecher A</searchLink>; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, United States.<br /><searchLink fieldCode="AU" term="%22Robinson+J%22">Robinson J</searchLink>; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Read+J%22">Read J</searchLink>; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Code+E%22">Code E</searchLink>; Discovery Sciences R&D, 35 Gatehouse Drive, Waltham, MA 02451, United States.<br /><searchLink fieldCode="AU" term="%22Hsu+JH%22">Hsu JH</searchLink>; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, United States.<br /><searchLink fieldCode="AU" term="%22Shen+M%22">Shen M</searchLink>; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, United States.<br /><searchLink fieldCode="AU" term="%22Woods+H%22">Woods H</searchLink>; Oncology R&D, AstraZeneca, 35 Gatehouse Drive, Waltham, MA 02451, United States.<br /><searchLink fieldCode="AU" term="%22Barton+P%22">Barton P</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Fillery+S%22">Fillery S</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Williamson+B%22">Williamson B</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Rawlins+PB%22">Rawlins PB</searchLink>; Discovery Sciences R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom.<br /><searchLink fieldCode="AU" term="%22Bagal+SK%22">Bagal SK</searchLink>; Oncology R&D, AstraZeneca, Cambridge CB4 0WG, United Kingdom. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229107377%22">Bioorganic & medicinal chemistry letters</searchLink> [Bioorg Med Chem Lett] 2021 May 01; Vol. 39, pp. 127904. <i>Date of Electronic Publication: </i>2021 Mar 06. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science+Ltd%22">Elsevier Science Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>9107377 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1464-3405 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220960894X%22">0960894X </searchLink><i>NLM ISO Abbreviation: </i>Bioorg Med Chem Lett <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=33684441 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.bmcl.2021.127904 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 127904 Titles: – TitleFull: Free energy perturbation in the design of EED ligands as inhibitors of polycomb repressive complex 2 (PRC2) methyltransferase. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: O' Donovan DH – PersonEntity: Name: NameFull: Gregson C – PersonEntity: Name: NameFull: Packer MJ – PersonEntity: Name: NameFull: Greenwood R – PersonEntity: Name: NameFull: Pike KG – PersonEntity: Name: NameFull: Kawatkar S – PersonEntity: Name: NameFull: Bloecher A – PersonEntity: Name: NameFull: Robinson J – PersonEntity: Name: NameFull: Read J – PersonEntity: Name: NameFull: Code E – PersonEntity: Name: NameFull: Hsu JH – PersonEntity: Name: NameFull: Shen M – PersonEntity: Name: NameFull: Woods H – PersonEntity: Name: NameFull: Barton P – PersonEntity: Name: NameFull: Fillery S – PersonEntity: Name: NameFull: Williamson B – PersonEntity: Name: NameFull: Rawlins PB – PersonEntity: Name: NameFull: Bagal SK IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 05 Text: 2021 May 01 Type: published Y: 2021 Identifiers: – Type: issn-electronic Value: 1464-3405 Numbering: – Type: volume Value: 39 Titles: – TitleFull: Bioorganic & medicinal chemistry letters Type: main |
| ResultId | 1 |